629 related articles for article (PubMed ID: 28877967)
1. Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.
Glasgow NG; Povysheva NV; Azofeifa AM; Johnson JW
J Neurosci; 2017 Oct; 37(40):9686-9704. PubMed ID: 28877967
[TBL] [Abstract][Full Text] [Related]
2. Effects of Mg
Glasgow NG; Wilcox MR; Johnson JW
Neuropharmacology; 2018 Jul; 137():344-358. PubMed ID: 29793153
[TBL] [Abstract][Full Text] [Related]
3. Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine.
Emnett CM; Eisenman LN; Taylor AM; Izumi Y; Zorumski CF; Mennerick S
Mol Pharmacol; 2013 Dec; 84(6):935-47. PubMed ID: 24101301
[TBL] [Abstract][Full Text] [Related]
4. Recent insights into the mode of action of memantine and ketamine.
Johnson JW; Glasgow NG; Povysheva NV
Curr Opin Pharmacol; 2015 Feb; 20():54-63. PubMed ID: 25462293
[TBL] [Abstract][Full Text] [Related]
5. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.
Kotermanski SE; Johnson JW
J Neurosci; 2009 Mar; 29(9):2774-9. PubMed ID: 19261873
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of action determine inhibition of paroxysmal depolarizing shifts by NMDA receptor antagonists in rat cortical neurons.
Nikolaev MV; Chizhov AV; Tikhonov DB
Neuropharmacology; 2021 Feb; 184():108443. PubMed ID: 33345828
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.
Gideons ES; Kavalali ET; Monteggia LM
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8649-54. PubMed ID: 24912158
[TBL] [Abstract][Full Text] [Related]
8. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
Gilling KE; Jatzke C; Hechenberger M; Parsons CG
Neuropharmacology; 2009 Apr; 56(5):866-75. PubMed ID: 19371579
[TBL] [Abstract][Full Text] [Related]
9. Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones.
Wild AR; Akyol E; Brothwell SL; Kimkool P; Skepper JN; Gibb AJ; Jones S
Neuropharmacology; 2013 Oct; 73():138-46. PubMed ID: 23727219
[TBL] [Abstract][Full Text] [Related]
10. Effects of memantine on the excitation-inhibition balance in prefrontal cortex.
Povysheva NV; Johnson JW
Neurobiol Dis; 2016 Dec; 96():75-83. PubMed ID: 27546057
[TBL] [Abstract][Full Text] [Related]
11. Tonically active NMDA receptors--a signalling mechanism critical for interneuronal excitability in the CA1 stratum radiatum.
Riebe I; Seth H; Culley G; Dósa Z; Radi S; Strand K; Fröjd V; Hanse E
Eur J Neurosci; 2016 Jan; 43(2):169-78. PubMed ID: 26547631
[TBL] [Abstract][Full Text] [Related]
12. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping.
Kotermanski SE; Wood JT; Johnson JW
J Physiol; 2009 Oct; 587(Pt 19):4589-604. PubMed ID: 19687120
[TBL] [Abstract][Full Text] [Related]
13. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.
Xia P; Chen HS; Zhang D; Lipton SA
J Neurosci; 2010 Aug; 30(33):11246-50. PubMed ID: 20720132
[TBL] [Abstract][Full Text] [Related]
14. Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.
Yi F; Bhattacharya S; Thompson CM; Traynelis SF; Hansen KB
J Physiol; 2019 Nov; 597(22):5495-5514. PubMed ID: 31541561
[TBL] [Abstract][Full Text] [Related]
15. The in vivo relevance of the varied channel-blocking properties of uncompetitive NMDA antagonists: tests on spinal neurones.
Jones MW; McClean M; Parsons CG; Headley PM
Neuropharmacology; 2001 Jul; 41(1):50-61. PubMed ID: 11445185
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NMDA receptors through a membrane-to-channel path.
Wilcox MR; Nigam A; Glasgow NG; Narangoda C; Phillips MB; Patel DS; Mesbahi-Vasey S; Turcu AL; Vázquez S; Kurnikova MG; Johnson JW
Nat Commun; 2022 Jul; 13(1):4114. PubMed ID: 35840593
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
18. GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms.
Ragnarsson L; Zhang Z; Das SS; Tran P; Andersson Å; des Portes V; Desmettre Altuzarra C; Remerand G; Labalme A; Chatron N; Sanlaville D; Lesca G; Anggono V; Vetter I; Keramidas A
Epilepsia; 2023 Dec; 64(12):3377-3388. PubMed ID: 37734923
[TBL] [Abstract][Full Text] [Related]
19. Developmental decrease in NMDA receptor desensitization associated with shift to synapse and interaction with postsynaptic density-95.
Li B; Otsu Y; Murphy TH; Raymond LA
J Neurosci; 2003 Dec; 23(35):11244-54. PubMed ID: 14657184
[TBL] [Abstract][Full Text] [Related]
20. 7-Methoxyderivative of tacrine is a 'foot-in-the-door' open-channel blocker of GluN1/GluN2 and GluN1/GluN3 NMDA receptors with neuroprotective activity in vivo.
Kaniakova M; Kleteckova L; Lichnerova K; Holubova K; Skrenkova K; Korinek M; Krusek J; Smejkalova T; Korabecny J; Vales K; Soukup O; Horak M
Neuropharmacology; 2018 Sep; 140():217-232. PubMed ID: 30099049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
